论文部分内容阅读
目的探讨重组人干扰素α-1b雾化吸入治疗儿童反复呼吸道感染临床疗效。方法将64例反复呼吸道感染患儿随机分为观察组34例和对照组30例,两组患儿都给予抗感染、退热、止咳、平喘等常规治疗,观察组在此基础上联合重组人干扰素α-1b雾化吸入。治疗前后分别抽取患儿静脉血行细胞免疫功能(CD3+、CD4+、CD8+)及体液免疫功能(IgG、IgA、IgM)检测。结果观察组总有效率明显高于对照组(P﹤0.05),观察组治疗后细胞免疫及体液免疫指标均较治疗前及对照组明显提高(P﹤0.05)。结论重组人干扰素α-1b雾化吸入治疗儿童反复呼吸道感染临床疗效确切,安全性好。
Objective To investigate the clinical efficacy of recombinant human interferon α-1b inhalation for recurrent respiratory tract infections in children. Methods Sixty-four children with recurrent respiratory tract infection were randomly divided into observation group (34 cases) and control group (30 cases). Both groups were given routine anti-infective, antipyretic, antitussive and antiasthmatic treatment. The observation group was combined with recombinant Human interferon alpha-1b aerosol inhalation. The levels of CD3 +, CD4 +, CD8 + and humoral immune function (IgG, IgA, IgM) were measured before and after treatment. Results The total effective rate in the observation group was significantly higher than that in the control group (P <0.05). The cellular immunity and humoral immunity of the observation group were significantly higher than those before treatment and the control group (P <0.05). Conclusions Recombinant human interferon α-1b aerosol inhalation for the treatment of recurrent respiratory tract infections in children is effective and safe.